These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 29658378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.
    Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1063-70. PubMed ID: 25490866
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
    Hwang YJ, Youn SW, Kim BR, Yu DY, Kim Y, Pires A, Cho S, Seo SJ, Lee ES, Roh JY, Choi GS, Lee MG, MARCOPOLO investigators.
    J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.
    J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [Abstract] [Full Text] [Related]

  • 20. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
    Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, Hession M, Lizzul PF, Andrews ID, Kerensky T, Wang A, Yaniv S, Gottlieb AB.
    J Dermatolog Treat; 2013 Jun; 24(3):179-87. PubMed ID: 22390688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.